Korean J Ophthalmol 2017;31(5):424-430 ht tps://doi.org/10.33 41/k jo.2016.0125

pISSN: 1011-8942 eISSN: 2092-9382

Original Article

Five-year Outcomes of Ranibizumab in Neovascular Age-related Macular Degeneration: Real Life Clinical Experience Abdullah Ozkaya, Zeynep Alkin, Mesut Togac, Sibel Ahmet, Irfan Perente, Muhittin Taskapili Beyoglu Eye Training and Research Hospital, Istanbul, Turkey

Purpose: To evaluate the outcomes of 5-year ranibizumab treatment in neovascular age-related macular degeneration (nAMD) in a single center and real life clinical setting. Methods: The records of nAMD patients who were treated with ranibizumab between January 2010 and June 2011 were retrospectively reviewed. Patients who completed 5 years of follow-up were included. Main outcome measures were change in best-corrected visual acuity, central retinal thickness, and visit and injection numbers. Results: Forty-four eyes of 37 patients were included. Mean best-corrected visual acuity decreased from 0.82 ± 0.69 to 1.11 ± 0.65 logarithm of minimal angle of resolution after 5 years. Twenty-four eyes (54.5%) had visual acuity loss ≥3 lines, and 20 eyes (45.5%) had stable or improved vision (loss

Five-year Outcomes of Ranibizumab in Neovascular Age-related Macular Degeneration: Real Life Clinical Experience.

To evaluate the outcomes of 5-year ranibizumab treatment in neovascular age-related macular degeneration (nAMD) in a single center and real life clini...
438KB Sizes 0 Downloads 6 Views